4/A: Allarity Therapeutics Director Laura Benjamin Corrects Stock Option Filing

Director Laura Benjamin of Allarity Therapeutics files an amended form to correct errors in the original filing regarding stock option vesting and expiration dates.

Summary

• Laura Benjamin, a director at Allarity Therapeutics, filed an amended Form 4/A to correct errors in a previous filing.
• The original filing incorrectly stated the expiration date of stock options as January 22, 2030, and the vesting date as the grant date.
• The corrected filing shows the stock options, granted on January 22, 2025, vest 100% on the anniversary of the grant date and are exercisable from that date.
• The corrected expiration date for the options is January 22, 2035.
• The options are for 25,000 shares of common stock at an exercise price of $1.01.

Sentiment

Score: 7

Explanation: The document is a routine correction of a filing, indicating no significant positive or negative sentiment. The correction is a positive for accuracy and compliance.

Industry Context

This filing is a routine disclosure of stock option grants to a company director, which is common practice in publicly traded companies. The correction of the filing is a standard procedure to ensure accuracy and compliance with SEC regulations.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors and executives in publicly traded companies.
• The vesting schedule of 100% on the anniversary of the grant is a typical vesting structure.
• The exercise price of $1.01 is a standard practice, often set at or near the market price at the time of the grant.
• The 10-year expiration period is also a common practice for stock options.

Stakeholder Impact

• The correction of the filing ensures transparency for shareholders regarding director compensation.
• The corrected information provides accurate details for investors tracking insider transactions.

Key Dates

Keywords

stock options, insider trading, form 4, beneficial ownership, equity incentive plan, Allarity Therapeutics, ALLR, Laura Benjamin